Cofoe Medical Technology Co.,Ltd. (referred to as "Cofoe Medical") released its third-quarter 2025 financial report on the evening of October 29. The report shows the company achieved quarterly revenue of 902 million yuan, a year-on-year increase of 30.72%, with net profit attributable to shareholders reaching 92.83 million yuan, up 38.68% year-on-year. Adjusted net profit grew 62.68% to 85.8 million yuan, marking record highs for both revenue and profit in the same period.
While maintaining steady performance growth, Cofoe Medical is accelerating its global expansion strategy. The company recently submitted a listing application to the Hong Kong Stock Exchange for a potential main board IPO, which would make it a dual-listed company on both A-share and H-share markets. This move is expected to broaden its global financing channels and enhance international brand recognition.
In recent years, Cofoe Medical has consistently implemented its dual-drive strategy of "product innovation + channel upgrade," with core product categories showing steady growth. According to Frost & Sullivan data, the company ranked second among Chinese home medical device enterprises in 2024, with its rehabilitation aids products taking the top position.
The company has significantly increased R&D investment to expand its intelligent and digital product portfolio. New products including portable ventilators, dual-test strips for blood glucose and uric acid, next-generation bone conduction hearing aids, and tunnel-type blood pressure monitors have been launched, strengthening its "home health management" product matrix while significantly improving product value-added and technological barriers.
Notably, the next-generation bone conduction hearing aid co-developed with Tencent demonstrates up to 85% improvement in speech clarity and intelligibility in complex noise environments. Equipped with deep learning-based acoustic scene recognition technology, the device can automatically adjust noise reduction, gain and directional processing for various environments including restaurants, streets and windy conditions, delivering more natural and precise listening experiences.
Beyond strong financial performance, Cofoe Medical's Hong Kong IPO prospectus has drawn considerable market attention. The filing indicates that proceeds will primarily fund global brand building, overseas channel expansion and innovation R&D to strengthen international operational capabilities.
Industry analysts note that a Hong Kong listing would not only optimize the company's capital structure and financing efficiency but also enhance its competitiveness in the global home medical device market. With the deepening implementation of China's "Healthy China 2030" strategy and accelerating population aging trends, the home medical device sector is experiencing structural growth opportunities. Leveraging its full-industry-chain presence and brand advantages, Cofoe Medical is positioned for new high-quality growth across domestic and international markets.
Looking ahead, company executives stated Cofoe Medical will maintain innovation as its core driver, focusing on home healthcare, chronic disease management and smart medical solutions. The Hong Kong listing will serve as a platform to integrate global resources and advance internationalization strategies, with the goal of building a world-leading medical device brand.
Comments